Search Results

You are looking at 1 - 7 of 7 items for :

  • pharmacokinetics x
  • Neurobiology x
Clear All
Open access

Piotr Boguta, Dariusz Juchnowicz, Paulina Wróbel-Knybel, Agnieszka Biała-Kędra and Hanna Karakuła-Juchnowicz

, Mancuso A, Andò G, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018; 14:1057-1069. 5. Dexxience [EU]. BevyxXa [US] · Venous thromboemolism (VTE) prevention - first line - in at risk adult patients hospitalised for an acute medical illness [Cited 13.01.2019]. Accessible at: https://www.sps.nhs.uk/medicines/betrixaban/ 6. Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants

Open access

Johad Khoury, Elias Andrawus, Boaz Y. Bishop and Zaher S. Azzam

, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30, 239–245, 1981. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 46, 1179–1187, 2006. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes

Open access

Sona Scsukova, Mlynarcikova A. Bujnakova, A. Kiss and E. Rollerova

drug carriers. Adv Clin Exp Med 24, 749-758, 2015. Oberdoster G. Safety assessment for nanotechnology and nanomedicine: concept of nanotoxicology. J Intern Med 267, 89-105, 2009. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 163, 93-99, 2012. Pelham RW, Nix LC, Chavira RE, Cleveland MVB, Stetson P. Clinical trial: si ngle- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in young and elderly subjects. Aliment

Open access

Agnieszka Pedrycz and Agnieszka Kramkowska

): 270-281. 8. Wcisło G., Korniluk J., Szarlej-Wcisło K., Pawlak W.Z., Nurzyński P., Duchnowska R.: Leczenie chorób nowotworowych czynnikiem martwicy nowotworów – alfa (TNF-alfa). Współczesna Onkologia, 2002; 4: 222–227. 9. Gabizon et al . Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436. 10. National Institute for Health and Clinical Excellence; TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydro-chloride and topotecan (review): Guidance

Open access

F. A. Farrugia, G. Martikos, C. Surgeon, P. Tzanetis, E. Misiakos, N. Zavras and A. Charalampopoulos

. Unal E, Karaosmanoglu A, Akata D, Ozmen MN, Karcaaltincaba M. Invisible fat on CT: making it visible by MRI. Diagn Interv Radiol 22, 133-140, 2016. van Niel MB, Collins I, Beer MS, Broughton HB, Cheng SK, Goodacre SC, Heald A, Locker KL, MacLeod AM, Morrison D, Moyes CR, O’Connor D, Pike A, Rowley M, Russell MG, Sohal B, Stanton JA, Th omas S, Verrier H, Watt AP, Castro JL. Fluorination of 3-(3-(piperidin-1-yl) propyl) indoles and 3-(3-(piperazin-1-yl) propyl) indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profi

Open access

Frederick-Anthony Farrugia, Nicolaos Zavras, Georgios Martikos, Panagiotis Tzanetis, Anestis Charalampopoulos, Evangelos P. Misiakos, Dimitrios Sotiropoulos and Nikolaos Koliakos

, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 134, 628-632, 1999. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10, 23-29, 2005. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J

Open access

Terezia Valkovicova, Martina Skopkova, Juraj Stanik and Daniela Gasperikova

subtypes. Diabetologia 54, 2801–2810, 2011. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron. Pharmacogenomics J 12, 22–29, 2012. Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug Tramadol. Clin Pharmacol Ther 90, 143–150, 2011